TriSalus Life Sciences, Inc. (TLSI) – What Are Brokerages Saying About This Stock?

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have earned an average rating of “Hold” from the five analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $10.20.

Several brokerages recently commented on TLSI. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a report on Wednesday, September 23rd. Finally, HC Wainwright lifted their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd.

TriSalus Life Sciences Trading Down 1.7%

TLSI stock opened at $4.06 on Friday. The company has a market cap of $250.01 million, a P/E ratio of -3.12 and a beta of 0.47. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. The business has a fifty day moving average of $4.88 and a 200-day moving average of $4.33.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million. As a group, equities research analysts expect that TriSalus Life Sciences will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Cura Wealth Advisors LLC bought a new stake in TriSalus Life Sciences during the 2nd quarter worth about $36,000. Renaissance Technologies LLC acquired a new position in shares of TriSalus Life Sciences during the 1st quarter worth about $124,000. Deutsche Bank AG acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth about $221,000. Sei Investments Co. acquired a new position in shares of TriSalus Life Sciences during the 1st quarter worth about $275,000. Finally, Bank of New York Mellon Corp bought a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at about $507,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is an oncology-focused life sciences company developing medical technologies and therapies for patients with difficult-to-treat liver and pancreatic tumors. The company’s approach is designed to address the unique biological and physical barriers that can limit the delivery of cancer treatments to solid tumors.

TriSalus’ principal technology is its Pressure-Enabled Drug Delivery (PEDD) platform, which is intended to improve the distribution of therapeutic agents within tumors through regional infusion.